Sevelamer Hydrochloride Exacerbates Metabolic Acidosis in Hemodialysis Patients, Depending on the Dosage
: Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study o...
Saved in:
| Published in | Therapeutic apheresis and dialysis Vol. 11; no. 2; pp. 107 - 113 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Melbourne, Australia
Blackwell Publishing Asia
01.04.2007
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1744-9979 1744-9987 |
| DOI | 10.1111/j.1744-9987.2007.00432.x |
Cover
| Abstract | : Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty‐six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the ‘sevelamer group’, and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t‐test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose‐dependent manner in hemodialysis patients without hyperchloremia. |
|---|---|
| AbstractList | Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty‐six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the ‘sevelamer group’, and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a
t
‐test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose‐dependent manner in hemodialysis patients without hyperchloremia. : Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty‐six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the ‘sevelamer group’, and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t‐test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose‐dependent manner in hemodialysis patients without hyperchloremia. Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty-six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the 'sevelamer group', and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t-test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose-dependent manner in hemodialysis patients without hyperchloremia. Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty-six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the 'sevelamer group', and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t-test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose-dependent manner in hemodialysis patients without hyperchloremia.Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty-six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the 'sevelamer group', and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t-test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose-dependent manner in hemodialysis patients without hyperchloremia. |
| Author | Oka, Yoshinari Uno, Futoshi Kunitomo, Kei-ichi Maruyama, Masanobu Miyazaki, Masashi Matsuda, Hiroaki Takatsu, Shigeko |
| Author_xml | – sequence: 1 givenname: Yoshinari surname: Oka fullname: Oka, Yoshinari email: saiwai@io.ocn.ne.jp organization: Departments of Surgery and – sequence: 2 givenname: Masashi surname: Miyazaki fullname: Miyazaki, Masashi organization: Departments of Surgery and – sequence: 3 givenname: Shigeko surname: Takatsu fullname: Takatsu, Shigeko organization: Internal Medicine, Saiwai-cho Memorial Hospital, and – sequence: 4 givenname: Kei-ichi surname: Kunitomo fullname: Kunitomo, Kei-ichi organization: Departments of Surgery and – sequence: 5 givenname: Futoshi surname: Uno fullname: Uno, Futoshi organization: Department of Digestive Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan – sequence: 6 givenname: Masanobu surname: Maruyama fullname: Maruyama, Masanobu organization: Department of Digestive Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan – sequence: 7 givenname: Hiroaki surname: Matsuda fullname: Matsuda, Hiroaki organization: Department of Digestive Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17381531$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV1v0zAYhS20iX2wv4B8xRUJ_kqcSAip-2CdNKDSOkDcWLbzZnVJ4mKn0P57Ejp6wQ3zjV_L5zmWzzlBB53vACFMSUqH9WaZUilEUpaFTBkhMiVEcJZunqHj_cXBfpblETqJcUkIY4Lz5-iISl7QjNNjtLiDn9DoFgKebqvg7aLxwVWArzbaQjC6h4g_QK-Nb5zFE-sqH13ErsNTaH3ldLMdzzPdO-j6-Bpfwgq6ynUP2He4XwC-9FE_wAt0WOsmwtnjforu31_NL6bJ7afrm4vJbWIFK1jCJK1NDqTmWZFpMJwzwmmZ59bWVlpiRKmLkhhmSmarTGhhhRGCapHpsiCGn6JXO99V8D_WEHvVumihaXQHfh2VJJzknJeD8OWjcG1aqNQquFaHrfqbzSB4txPY4GMMUCvr-uGbvuuDdo2iRI1lqKUac1Zj5mosQ_0pQ20Gg-Ifg_0b_0ff7tBfroHtkzk1n8yGYcCTHe5iD5s9rsN3lUsuM_Xl47U6P_88_Tb7ytSc_wZqYrC7 |
| CitedBy_id | crossref_primary_10_1111_1744_9987_12052 crossref_primary_10_1111_1744_9987_12461 crossref_primary_10_1185_03007995_2013_838551 crossref_primary_10_1080_08860220802381893 crossref_primary_10_1093_ndt_gfq682 crossref_primary_10_1016_j_nephro_2014_04_001 crossref_primary_10_1093_ndt_gfw312 crossref_primary_10_1007_s40265_014_0215_7 crossref_primary_10_1093_ndtplus_sfn034 crossref_primary_10_1016_j_tox_2008_03_012 crossref_primary_10_1111_j_1744_9987_2010_00868_x crossref_primary_10_1186_1471_2369_14_205 crossref_primary_10_3109_0886022X_2014_976160 crossref_primary_10_1016_j_dialis_2010_07_006 crossref_primary_10_1111_1744_9987_12502 crossref_primary_10_1517_14656566_2010_526107 crossref_primary_10_1016_j_jfms_2009_09_012 crossref_primary_10_1517_14656566_2013_852183 crossref_primary_10_1592_phco_29_5_554 |
| Cites_doi | 10.1053/ajkd.1998.v31.pm9531176 10.1046/j.1523-1755.2002.00434.x 10.1111/j.1744-9987.2005.00294.x 10.1016/S0272-6386(12)70364-5 10.1093/ndt/gfh125 10.1046/j.1523-1755.2000.00025.x 10.1081/JDI-200048238 10.1016/S0272-6386(04)00936-9 10.1111/j.1523-1755.2004.09007.x 10.1159/000072822 10.1111/j.1523-1755.2004.00590.x 10.1159/000063307 |
| ContentType | Journal Article |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/j.1744-9987.2007.00432.x |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1744-9987 |
| EndPage | 113 |
| ExternalDocumentID | 17381531 10_1111_j_1744_9987_2007_00432_x TAP432 ark_67375_WNG_BBVHZPX2_T |
| Genre | article Clinical Trial Journal Article |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 29Q 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 ~IA ~WT AAHHS ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE WRC AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c4282-271fb6e0f3585aeb332031966ccfc7c0b49a890b2b92cd54a4c4b441a45a980b3 |
| IEDL.DBID | DR2 |
| ISSN | 1744-9979 |
| IngestDate | Fri Jul 11 16:54:35 EDT 2025 Wed Feb 19 01:41:46 EST 2025 Wed Oct 01 03:56:25 EDT 2025 Thu Apr 24 23:04:18 EDT 2025 Wed Jan 22 16:30:34 EST 2025 Tue Sep 09 05:30:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4282-271fb6e0f3585aeb332031966ccfc7c0b49a890b2b92cd54a4c4b441a45a980b3 |
| Notes | ark:/67375/WNG-BBVHZPX2-T ArticleID:TAP432 istex:F3DAB781B6B982D5BC5DBF656FF1616D9CD33A02 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 17381531 |
| PQID | 70306339 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_70306339 pubmed_primary_17381531 crossref_citationtrail_10_1111_j_1744_9987_2007_00432_x crossref_primary_10_1111_j_1744_9987_2007_00432_x wiley_primary_10_1111_j_1744_9987_2007_00432_x_TAP432 istex_primary_ark_67375_WNG_BBVHZPX2_T |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2007-04 April 2007 2007-04-00 2007-Apr 20070401 |
| PublicationDateYYYYMMDD | 2007-04-01 |
| PublicationDate_xml | – month: 04 year: 2007 text: 2007-04 |
| PublicationDecade | 2000 |
| PublicationPlace | Melbourne, Australia |
| PublicationPlace_xml | – name: Melbourne, Australia – name: Australia |
| PublicationTitle | Therapeutic apheresis and dialysis |
| PublicationTitleAlternate | Ther Apher Dial |
| PublicationYear | 2007 |
| Publisher | Blackwell Publishing Asia |
| Publisher_xml | – name: Blackwell Publishing Asia |
| References | Edmung G, Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002;92:499-500. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66:39-45. Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14. Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:12-28. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int 2000;57:1776-7. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96. Macroui A, Sonikian MA, Pani IT et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26. 2004; 65 2004; 66 2004; 44 1990; 15 2004; 19 2002; 62 2000; 57 2005; 9 2002; 92 2005; 27 1998; 31 2003; 42 2003; 23 National Kidney Foundation. (e_1_2_6_9_2) 2003; 42 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_2_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_14_2 |
| References_xml | – reference: Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int 2000;57:1776-7. – reference: Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52. – reference: Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14. – reference: Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6. – reference: Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17. – reference: Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96. – reference: National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:12-28. – reference: Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26. – reference: Edmung G, Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82. – reference: Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66:39-45. – reference: Macroui A, Sonikian MA, Pani IT et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7. – reference: Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002;92:499-500. – reference: Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71. – volume: 42 start-page: 12 year: 2003 end-page: 28 article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease publication-title: Am J Kidney Dis – volume: 15 start-page: 458 year: 1990 end-page: 82 article-title: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities publication-title: Am J Kidney Dis – volume: 31 start-page: 607 year: 1998 end-page: 17 article-title: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study publication-title: Am J Kidney Dis – volume: 9 start-page: 340 year: 2005 end-page: 6 article-title: Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan publication-title: Ther Apher Dial – volume: 62 start-page: 245 year: 2002 end-page: 52 article-title: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients publication-title: Kidney Int – volume: 27 start-page: 143 year: 2005 end-page: 7 article-title: Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride publication-title: Ren Fail – volume: 65 start-page: 1914 year: 2004 end-page: 26 article-title: Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study) publication-title: Kidney Int – volume: 57 start-page: 1776 year: 2000 end-page: 7 article-title: Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder publication-title: Kidney Int – volume: 66 start-page: 39 year: 2004 end-page: 45 article-title: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications publication-title: Kidney Int – volume: 44 start-page: 661 year: 2004 end-page: 71 article-title: Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS) publication-title: Am J Kidney Dis – volume: 23 start-page: 307 year: 2003 end-page: 14 article-title: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients publication-title: Am J Nephrol – volume: 19 start-page: 1489 year: 2004 end-page: 96 article-title: Determinants of progressive vascular calcification in haemodialysis patients publication-title: Nephrol Dial Transplant – volume: 92 start-page: 499 year: 2002 end-page: 500 article-title: Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients publication-title: Nephron – ident: e_1_2_6_3_2 doi: 10.1053/ajkd.1998.v31.pm9531176 – volume: 42 start-page: 12 year: 2003 ident: e_1_2_6_9_2 article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease publication-title: Am J Kidney Dis – ident: e_1_2_6_4_2 doi: 10.1046/j.1523-1755.2002.00434.x – ident: e_1_2_6_13_2 doi: 10.1111/j.1744-9987.2005.00294.x – ident: e_1_2_6_2_2 doi: 10.1016/S0272-6386(12)70364-5 – ident: e_1_2_6_6_2 doi: 10.1093/ndt/gfh125 – ident: e_1_2_6_12_2 doi: 10.1046/j.1523-1755.2000.00025.x – ident: e_1_2_6_8_2 doi: 10.1081/JDI-200048238 – ident: e_1_2_6_10_2 doi: 10.1016/S0272-6386(04)00936-9 – ident: e_1_2_6_7_2 doi: 10.1111/j.1523-1755.2004.09007.x – ident: e_1_2_6_5_2 doi: 10.1159/000072822 – ident: e_1_2_6_14_2 doi: 10.1111/j.1523-1755.2004.00590.x – ident: e_1_2_6_11_2 doi: 10.1159/000063307 |
| SSID | ssj0022433 |
| Score | 1.8594898 |
| Snippet | : Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients.... Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However,... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 107 |
| SubjectTerms | Acidosis - drug therapy Bicarbonate Bicarbonates - analysis Chelating Agents - therapeutic use Dose-Response Relationship, Drug Female Hemodialysis Humans Hydrogen-Ion Concentration Male Metabolic acidosis Middle Aged Non-anion gap acidosis Polyamines - therapeutic use Renal Dialysis - methods Sevelamer Sevelamer hydrochloride |
| Title | Sevelamer Hydrochloride Exacerbates Metabolic Acidosis in Hemodialysis Patients, Depending on the Dosage |
| URI | https://api.istex.fr/ark:/67375/WNG-BBVHZPX2-T/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1744-9987.2007.00432.x https://www.ncbi.nlm.nih.gov/pubmed/17381531 https://www.proquest.com/docview/70306339 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1744-9979 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1744-9987 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022433 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELemIU28ABtfAbb5Ae2JVEns2Mlj9xkhdapYBxUvlu04ouqWoKaVCn89d0la1mkPE-LNL-fE5zvf7-z7IORj6OJcxFHiM8cDn6e59hOXC59LHScFOAipxQv9waXIrvnncTzu4p8wF6atD7G-cEPNaM5rVHBt6k0ll5z74C7IVSVCzqIe4smQica7-rKuJAWGqukq35HI9H5QzwMTbViqJ8j05UMwdBPVNmbp_DmZrhbURqNMe4u56dnf92o9_p8VvyDPOvRK-6247ZItV-6RnUH3Pv-S_LjCGCR962Y0-5VjNy4M8MsdPVtqCxuIwJYO3Bwk72Ziad9O8qqe1HRS0szdVpjEghVS6LCt9lp_oqdNk16wr7QqKYBVelphKNwrcn1-NjrJ_K6Xg2_BwcEMoLAwwgUFA_9EgwfPIsyfEsLawkobGJ7qJA1MZNLI5jHX3HIDUE3zWKdJYNhrsl1WpXtLqMPEAZPkMBEHdxSGSSGATmhWJKGWHpGrfVO2K3SO_TZu1B2HBxipkJHYhhNf4IGRaumRcE35sy328Qiao0Y01gR6NsVgORmrb5cX6vj4a_Z9OI7UyCOHK9lRoML4LqNLVy1qhYeuYCz1yJtWpP5-XAKgglPSI3EjGI_-KzXqD2Hw7h_p3pOn7R02Rih9INvz2cLtA_iam4NGrf4A0NkehQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-hTQJeGJ8j42N-QDyRKk0cO3ns2EaAtaqgg4oXy3YcUa1LUD-kwl_PXZIWOu1hQrz55ZzYvvP97nwfAK-6Ls5FHCZ-5Hjg8zTXfuJy4XOp46RAAyG15NDvD0R2zj-M43HbDohyYZr6EBuHG0lGfV-TgJNDelvKJec-2gtyXYqQR2EHAeUuF2i2EEL6tKklhaqq7ivf0sj0aljPNTNt6apd2vbVdUB0G9fWiul0D6brJTXxKBed5cJ07K8r1R7_05rvw70WwLJew3EP4JYrH8LtfvtE_wi-f6YwJH3pZiz7mVNDLorxyx07WWmLZ0jYlvXdAplvOrGsZyd5NZ_M2aRkmbusKI-FiqSwYVPwdf6GHdd9elHFsqpkiFfZcUXRcI_h_PRk9Dbz23YOvkUbh5KAuoURLigiNFE0GvFRSClUQlhbWGkDw1OdpIEJTRraPOaaW24QrWke6zQJTPQEdsqqdE-BOcodMEmOE3G0SHGYFALphI6KpKulB3J9cMq2tc6p5cZU_WXz4EYq2kjqxEmP8LiRauVBd0P5o6n3cQOa1zVvbAj07ILi5WSsvg7eqaOjL9m34ThUIw8O18yjUIrpaUaXrlrOFd27IopSD_YbnvrzcYmYCi9KD-KaM278V2rUG-Lg4B_pDuFONuqfqbP3g4_P4G7j0qaApeews5gt3QvEYgvzspax39R8IqY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-hTZp4gY2vBRjzA-KJVGliJ85jt66Ej1YVdFDxYjmOI6p1ydQPqeOv312SFjrtYUK8-eWc-Hzn-519HwBv21ZkofClG1juuTzOtCttFro80kLm6CDEhi70-4MwOeefxmLctAOiXJi6PsTmwo00ozqvScHtVZZva3nEuYv-QrQuRcgDv4WAcpeLWFJ8X_frppYUmqqqr3xDE8W3w3rumGnLVu0S21d3AdFtXFsZpt5jmK6XVMejXLSWi7Rlft-q9vif1rwPjxoAyzq1xB3AA1s8gb1-80T_FH59ozAkfWlnLLnOqCEXxfhllp2ttME9JGzL-naBwjedGNYxk6ycT-ZsUrDEXpaUx0JFUtiwLvg6f8-6VZ9eNLGsLBjiVdYtKRruGZz3zkanidu0c3AN-jiUBNTO09B6eYAuikYnPvAphSoMjclNZLyUx1rGXuqnsW8ywTU3PEW0prnQsfTS4DnsFGVhD4FZyh1IZYYTcfRIcSjzEOlCHeSyrSMHovXGKdPUOqeWG1P1l8-DjFTESOrESY_wyEi1cqC9obyq633cg-ZdJRsbAj27oHi5SKgfgw_q5OR78nM49tXIgeO18CjUYnqa0YUtl3NF524YBLEDL2qZ-vPxCDEVHpQOiEoy7v1XatQZ4uDlP9Idw96w21NfPg4-v4KH9Y02xSu9hp3FbGmPEIot0jeVit0AS0IiKg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sevelamer+Hydrochloride+Exacerbates+Metabolic+Acidosis+in+Hemodialysis+Patients%2C+Depending+on+the+Dosage&rft.jtitle=Therapeutic+apheresis+and+dialysis&rft.au=Oka%2C+Yoshinari&rft.au=Miyazaki%2C+Masashi&rft.au=Takatsu%2C+Shigeko&rft.au=Kunitomo%2C+Kei%E2%80%90ichi&rft.date=2007-04-01&rft.issn=1744-9979&rft.eissn=1744-9987&rft.volume=11&rft.issue=2&rft.spage=107&rft.epage=113&rft_id=info:doi/10.1111%2Fj.1744-9987.2007.00432.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1744_9987_2007_00432_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1744-9979&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1744-9979&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1744-9979&client=summon |